Payment overview · 2025
General Payments
$21,743.88
145 reported records · 33 companies
Healthcare provider profile · identity verified
Steve W Rucker, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Nephrology · LAKE SUCCESS, NY · NPI 1083712806
Verified facts
What the public records show
CMS Open Payments records show Steve W Rucker, MD received $21,743.88 in general payments during 2025 across 145 reported records.
Boehringer Ingelheim Pharmaceuticals, Inc. accounted for 79.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 51 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Jynarque, Linzess, Mounjaro, Ozempic, Rayaldee, Veltassa.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 162 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Lokelma by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Ozempic by this doctor in 2024.
OPKO Pharmaceuticals, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RAYALDEE as an associated drug or biological on 5435 records involving 1739 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Rayaldee by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JYNARQUE as an associated drug or biological on 11133 records involving 4164 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Jynarque by this doctor in 2024.
Otsuka Pharmaceutical Development & Commercialization, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JYNARQUE as an associated drug or biological on 38 records involving 37 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Jynarque by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Paxlovid by this doctor in 2024.
Vifor Pharma, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Veltassa as an associated drug or biological on 5970 records involving 2480 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Veltassa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17,210.03 | 79.2% | 21 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $1,972.81 | 9.1% | 8 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $296.81 | 1.4% | 19 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $273.71 | 1.3% | 13 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $267.82 | 1.2% | 5 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $205.27 | 0.9% | 12 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $196.62 | 0.9% | 10 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $170.68 | 0.8% | 11 | 2025 |
| Travere Therapeutics, Inc. | Unresolved — no canonical attribution shown | $141.47 | 0.7% | 6 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$131.03 | 0.6% | 1 | 2025 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | Unresolved — no canonical attribution shown | $94.28 | 0.4% | 1 | 2025 |
| SCPHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $92.14 | 0.4% | 4 | 2025 |
| Mallinckrodt Hospital Products Inc. | Unresolved — no canonical attribution shown | $71.83 | 0.3% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $66.71 | 0.3% | 3 | 2025 |
| OPKO Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $65.41 | 0.3% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $65.36 | 0.3% | 4 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $44.59 | 0.2% | 2 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $43.50 | 0.2% | 2 | 2025 |
| Rhythm Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $37.90 | 0.2% | 2 | 2025 |
| Mannkind Corporation | Unresolved — no canonical attribution shown | $25.10 | 0.1% | 1 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $25.00 | 0.1% | 1 | 2025 |
| AKEBIA THERAPEUTICS INC | Unresolved — no canonical attribution shown | $24.55 | 0.1% | 1 | 2025 |
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $24.24 | 0.1% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $23.85 | 0.1% | 1 | 2025 |
| CONMED Corporation | Unresolved — no canonical attribution shown | $23.65 | 0.1% | 1 | 2025 |
| Fresenius USA Manufacturing, Inc. | Unresolved — no canonical attribution shown | $23.13 | 0.1% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $22.05 | 0.1% | 1 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $21.09 | 0.1% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $20.00 | 0.1% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $17.02 | 0.1% | 1 | 2025 |
| Dynavax Technologies Corporation | Unresolved — no canonical attribution shown | $15.96 | 0.1% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $15.25 | 0.1% | 1 | 2025 |
| Vifor Pharma, Inc. | Unresolved — no canonical attribution shown | $15.02 | 0.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $16,420.00 | 11 |
| Food and Beverage | $3,017.79 | 125 |
| Travel and Lodging | $2,209.53 | 4 |
| Education | $96.56 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $19,075.42 | 24 | 2025 |
Source payment records
|
|||||
| JYNARQUE Normalized: jynarque |
Drug | Otsuka America Pharmaceutical, Inc. | $229.28 | 9 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $196.98 | 14 | 2025 |
Source payment records
|
|||||
| AVEIR Normalized: aveir |
Device | Abbott Laboratories | $193.45 | 2 | 2025 |
Source payment records
|
|||||
| SYMPLICITY G3 Normalized: symplicity g3 |
Device | Medtronic, Inc. | $131.03 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $116.76 | 6 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $112.34 | 11 | 2025 |
Source payment records
|
|||||
| Fabhalta Normalized: fabhalta |
Drug | Novartis Pharmaceuticals Corporation | $108.85 | 6 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $99.83 | 5 | 2025 |
Source payment records
|
|||||
| FUROSCIX Normalized: furoscix |
Drug | SCPHARMACEUTICALS INC. | $92.14 | 4 | 2025 |
Source payment records
|
|||||
| Vanrafia Normalized: vanrafia |
Drug | Novartis Pharmaceuticals Corporation | $87.39 | 5 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $78.47 | 6 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $75.59 | 5 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $74.37 | 3 | 2025 |
Source payment records
|
|||||
| RAYALDEE Normalized: rayaldee |
Drug | OPKO Pharmaceuticals, LLC | $65.41 | 4 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $65.36 | 4 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $65.36 | 4 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $64.34 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $62.42 | 4 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $54.55 | 5 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $52.34 | 3 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $44.59 | 2 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $43.50 | 2 | 2025 |
Source payment records
|
|||||
| TERLIVAZ Normalized: terlivaz |
Drug | Mallinckrodt Hospital Products Inc. | $43.03 | 2 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $42.05 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $41.64 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $41.64 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $41.64 | 2 | 2025 |
Source payment records
|
|||||
| IMCIVREE Normalized: imcivree |
Drug | Rhythm Pharmaceuticals, Inc. | $37.90 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $37.81 | 2 | 2025 |
Source payment records
|
|||||
| ACTHAR Normalized: acthar |
Biological | Mallinckrodt Hospital Products Inc. | $28.80 | 1 | 2025 |
Source payment records
|
|||||
| VOYXACT Normalized: voyxact |
Drug | Otsuka America Pharmaceutical, Inc. | $25.14 | 1 | 2025 |
Source payment records
|
|||||
| AFREZZA Normalized: afrezza |
Drug | Mannkind Corporation | $25.10 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $25.07 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $25.07 | 1 | 2025 |
Source payment records
|
|||||
| UNITHROID Normalized: unithroid |
Drug | Amneal Pharmaceuticals LLC | $25.00 | 1 | 2025 |
Source payment records
|
|||||
| Vafseo Normalized: vafseo |
Drug | AKEBIA THERAPEUTICS INC | $24.55 | 1 | 2025 |
Source payment records
|
|||||
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $24.24 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $23.85 | 1 | 2025 |
Source payment records
|
|||||
| CONMED BILIARY Normalized: conmed biliary |
Device | CONMED Corporation | $23.65 | 1 | 2025 |
Source payment records
|
|||||
| VELPHORO Normalized: velphoro |
Drug | Fresenius USA Manufacturing, Inc. | $23.13 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $22.05 | 1 | 2025 |
Source payment records
|
|||||
| RINVOQ Normalized: rinvoq |
Biological | ABBVIE INC. | $20.64 | 1 | 2025 |
Source payment records
|
|||||
| SKYRIZI Normalized: skyrizi |
Biological | ABBVIE INC. | $20.64 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $20.00 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $19.23 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $19.17 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $17.02 | 1 | 2025 |
Source payment records
|
|||||
| Heplisav-B Normalized: heplisav b |
Drug | Dynavax Technologies Corporation | $15.96 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $15.25 | 1 | 2025 |
Source payment records
|
|||||
| Veltassa Normalized: veltassa |
Drug | Vifor Pharma, Inc. | $15.02 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 56 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 59 | exact normalized | Medicare Part D |
| JYNARQUE jynarque |
2025 | Jynarque | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 50 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 80 | exact normalized | Medicare Part D |
| RAYALDEE rayaldee |
2025 | Rayaldee | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Veltassa veltassa |
2025 | Veltassa | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
71 | 28 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
162 | 55 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
59 | 25 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
59 | 25 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
50 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
80 | 16 |
| OPKO Pharmaceuticals, LLC Exact reporting entity; no affiliate inference |
2025 | RAYALDEE open payments reported associated product |
CMS Open Payments — General Payments 5435 supporting records · 1739 recipient NPIs · example record 1222072234 |
Rayaldee · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | JYNARQUE open payments reported associated product |
CMS Open Payments — General Payments 11133 supporting records · 4164 recipient NPIs · example record 1227267725 |
Jynarque · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Otsuka Pharmaceutical Development & Commercialization, Inc. Exact reporting entity; no affiliate inference |
2025 | JYNARQUE open payments reported associated product |
CMS Open Payments — General Payments 38 supporting records · 37 recipient NPIs · example record 1225320011 |
Jynarque · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
56 | 24 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
27 | 27 |
| Vifor Pharma, Inc. Exact reporting entity; no affiliate inference |
2025 | Veltassa open payments reported associated product |
CMS Open Payments — General Payments 5970 supporting records · 2480 recipient NPIs · example record 1172020739 |
Veltassa · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 363 | 147 |
| Atorvastatin Calcium | Atorvastatin Calcium | 337 | 133 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 334 | 128 |
| Losartan Potassium | Losartan Potassium | 253 | 101 |
| Levothyroxine Sodium | Levothyroxine Sodium | 241 | 92 |
| Alprazolam | Alprazolam | 232 | 86 |
| Valsartan | Valsartan | 226 | 86 |
| Zolpidem Tartrate | Zolpidem Tartrate | 189 | 67 |
| Metoprolol Succinate | Metoprolol Succinate | 181 | 78 |
| Farxiga | Dapagliflozin Propanediol | 162 | 55 |
| Torsemide | Torsemide | 148 | 64 |
| Tamsulosin Hcl | Tamsulosin Hcl | 134 | 50 |
| Allopurinol | Allopurinol | 128 | 49 |
| Escitalopram Oxalate | Escitalopram Oxalate | 118 | 44 |
| Diazepam | Diazepam | 111 | 36 |
| Metformin Hcl Er | Metformin Hcl | 111 | 44 |
| Simvastatin | Simvastatin | 107 | 44 |
| Gabapentin | Gabapentin | 105 | 38 |
| Pantoprazole Sodium | Pantoprazole Sodium | 103 | 42 |
| Hydrochlorothiazide | Hydrochlorothiazide | 101 | 43 |
| Furosemide | Furosemide | 81 | 36 |
| Ozempic | Semaglutide | 80 | 16 |
| Lisinopril | Lisinopril | 75 | 33 |
| Ezetimibe | Ezetimibe | 73 | 33 |
| Metformin Hcl | Metformin Hcl | 73 | 33 |
| Synthroid | Levothyroxine Sodium | 71 | 28 |
| Omeprazole | Omeprazole | 68 | 34 |
| Clonazepam | Clonazepam | 65 | 19 |
| Prednisone | Prednisone | 62 | 31 |
| Xarelto | Rivaroxaban | 61 | 17 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 60 | 29 |
| Jardiance | Empagliflozin | 59 | 25 |
| Famotidine | Famotidine | 58 | 25 |
| Irbesartan | Irbesartan | 58 | 24 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 57 | 18 |
| Carvedilol | Carvedilol | 56 | 18 |
| Eliquis | Apixaban | 56 | 24 |
| Lorazepam | Lorazepam | 54 | 18 |
| Ramipril | Ramipril | 54 | 18 |
| Mounjaro | Tirzepatide | 50 | 13 |
| Calcitriol | Calcitriol | 48 | 13 |
| Doxazosin Mesylate | Doxazosin Mesylate | 48 | 18 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 47 | 16 |
| Meloxicam | Meloxicam | 47 | 17 |
| Azithromycin | Azithromycin | 43 | 36 |
| Sertraline Hcl | Sertraline Hcl | 43 | 19 |
| Cephalexin | Cephalexin | 41 | 35 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 41 | 13 |
| Sevelamer Carbonate | Sevelamer Carbonate | 41 | 12 |
| Atenolol | Atenolol | 37 | 15 |
| Montelukast Sodium | Montelukast Sodium | 35 | 12 |
| Glimepiride | Glimepiride | 34 | 13 |
| Finasteride | Finasteride | 32 | 17 |
| Methylprednisolone | Methylprednisolone | 32 | 25 |
| Potassium Citrate Er | Potassium Citrate | 32 | 12 |
| Potassium Chloride | Potassium Chloride | 31 | 17 |
| Colchicine | Colchicine | 30 | 13 |
| Metoprolol Tartrate | Metoprolol Tartrate | 30 | 13 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 28 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 28 | 11 |
| Donepezil Hcl | Donepezil Hcl | 28 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 27 | suppressed |
| Nifedipine Er | Nifedipine | 27 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 27 | 27 |
| Clopidogrel | Clopidogrel Bisulfate | 26 | 11 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 26 | 24 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 25 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 25 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 25 | 11 |
| Cinacalcet Hcl | Cinacalcet Hcl | 24 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 24 | 12 |
| Trazodone Hcl | Trazodone Hcl | 24 | 13 |
| Bupropion Xl | Bupropion Hcl | 23 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 23 | 20 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 23 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 23 | 12 |
| Vascepa | Icosapent Ethyl | 23 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 22 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 22 | 13 |
| Multaq | Dronedarone Hcl | 22 | suppressed |
| Mupirocin | Mupirocin | 22 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 22 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 22 | suppressed |
| Levofloxacin | Levofloxacin | 21 | 19 |
| Mirtazapine | Mirtazapine | 21 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 20 | suppressed |
| Klor-Con M20 | Potassium Chloride | 20 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 20 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 20 | 11 |
| Rayaldee | Calcifediol | 20 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 20 | suppressed |
| Chlorthalidone | Chlorthalidone | 19 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 19 | suppressed |
| Calcium Acetate | Calcium Acetate | 18 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 18 | 17 |
| Duloxetine Hcl | Duloxetine Hcl | 18 | suppressed |
| Fentanyl | Fentanyl | 18 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 18 | suppressed |
| Spironolactone | Spironolactone | 18 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 16 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 16 | suppressed |
| Repaglinide | Repaglinide | 16 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 16 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 15 | 11 |
| Kerendia | Finerenone | 15 | suppressed |
| Amoxicillin | Amoxicillin | 14 | 11 |
| Digoxin | Digoxin | 14 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 14 | suppressed |
| Glipizide | Glipizide | 14 | suppressed |
| Hydrocortisone | Hydrocortisone | 14 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 13 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 13 | suppressed |
| Jynarque | Tolvaptan | 13 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 13 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 13 | suppressed |
| Veltassa | Patiromer Calcium Sorbitex | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Amlodipine-Atorvastatin | Amlodipine/Atorvastatin | 12 | suppressed |
| Januvia | Sitagliptin Phosphate | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 12 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 12 | suppressed |
| Prempro | Estrogen,con/M-Progest Acet | 12 | suppressed |
| Tacrolimus | Tacrolimus | 12 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 11 | suppressed |
| Bumetanide | Bumetanide | 11 | suppressed |
| Celecoxib | Celecoxib | 11 | suppressed |
| Dexilant | Dexlansoprazole | 11 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 11 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 11 | suppressed |
| Linzess | Linaclotide | 11 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 11 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 11 | suppressed |
| Sucralfate | Sucralfate | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $21,743.88 · 145 records | Boehringer Ingelheim Pharmaceuticals, Inc. | ABRYSVO, ACTHAR, AFREZZA, AREXVY, AVEIR, BREZTRI, CAPVAXIVE, COMIRNATY, CONMED BILIARY, CREON, ELIQUIS, EVENITY, FREESTYLE LIBRE 3, FUROSCIX, Fabhalta, Heplisav-B, IBSRELA, IMCIVREE, JARDIANCE, JYNARQUE, KRYSTEXXA, Korlym, LEQVIO, LINZESS, Leqembi, MOUNJARO, NEXLETOL, NURTEC ODT, OTEZLA, Ozempic, PREVNAR 20, RAYALDEE, REPATHA, REZDIFFRA, RINVOQ, Rybelsus, SHINGRIX, SKYRIZI, SYMPLICITY G3, TERLIVAZ, TZIELD, UBRELVY, UNITHROID, VELPHORO, VOYXACT, VRAYLAR, Vafseo, Vanrafia, Veltassa, Wegovy, ZEPBOUND | 15 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error